Clopidogrel Bisulfate
NDC Package 62034-017-73
Package Information
Clopidogrel Bisulfate is for patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization, clopidogrel has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. Marketed by Blenheim Pharmacal, Inc., this product is identified by NDC 62034-017 and is authorized under FDA application ANDA204165.
Identification & Billing
- RxCUI: 749196 - clopidogrel 300 MG Oral Tablet
- RxCUI: 749196 - clopidogrel 300 MG (as clopidogrel bisulfate 391.5 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 62034 - Blenheim Pharmacal, Inc.
- 62034-017 - Clopidogrel Bisulfate
- 62034-017-73 - 30 BLISTER PACK in 1 BOX, UNIT-DOSE / 1 TABLET, FILM COATED in 1 BLISTER PACK (62034-017-11)
- 62034-017 - Clopidogrel Bisulfate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 62034-017-73 identifies a specific commercial package of 30 blister pack in 1 box, unit-dose / 1 tablet, film coated in 1 blister pack (62034-017-11) of Clopidogrel Bisulfate, labeled by Blenheim Pharmacal, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Blenheim Pharmacal, Inc. on March 01, 2016. The current certification is valid through December 31, 2017.
How is this Blenheim Pharmacal, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 62034001773. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.